Choose a language and wait for the translated text.
Shots:
Merck has reported that the P-III TroFuse-015 trial evaluating sac-TMT, a TROP2-directed ADC licensed from Kelun-Biotech, met its 1EP of OS vs treatment of physician’s choice (TPC: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who received ≥2 prior lines of systemic therapy
At final analysis, sac-TMT showed a statistically significant & clinically meaningful OS improvement, with results generally consistent across subgroups regardless of TROP2 expression; the 2EP of PFS by BICR was not met, ORR nominally favored sac-TMT (not formally tested) & no new safety signals were observed
The global open-label trial (NCT06356311) randomized 473 patients; sac-TMT is the first TROP2 ADC to show an OS benefit in a global P-III study in this setting & the data will be presented at an upcoming medical meeting and shared with regulators. TroFuse-015 is the 2nd positive P-III readout from the TroFuse program, which includes 18 ongoing global P-III trials
Ref: Merck | Image: Merck | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma appeared first on PharmaShots.
Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma | PharmaVoice